Piper Jaffray analyst Christopher Raymond raised his price target for BioMarin Pharmaceutical to $120 and keeps an Overweight rating on the name following the company’s “solid” Q2 results. The analyst believes the Palynziq launch is going well and says BioMarin provided incrementally positive updates for hemophilia gene therapy candidate valrox. He sees a “credible chance” that BioMarin could file early for accelerated approval on valrox Phase 1 data. Raymond continues to like to setup for the stock and would be a buyer to levels approaching $120.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.